Background: Helicobacter pylori infection is a global public health problem and may be present in more than half of the world’s population  Prevalence in developing country higher compared to developed country. However, in Indonesia prevalence of Helicobacter pylori infection is still low compare to other Asian countries. This study aims to determine the prevalence of Helicobacter pylori infection in Abdi Waluyo Hospital Jakarta from January 2017 to December 2019.Method: In this cross sectional study, a total of 772 adult patients were tested using Urea Breath Test-14C for detection of isotopic carbon produced by Helicobacter pylori ability to broke down urea.Results: Prevalence of Helicobacter pylori infection in Abdi Waluyo hospital between January 2017 – December 2019 was 20.98% with endoscopic findings as follows: 17.48% with gastritis,  3.24% with gastric ulcers , 0.26% with gastric cancerConclusion: Increase prevalence of Helicobacter pylori infection every year in Abdi Waluyo hospital. It is suggested to perfom Urea Breath Test for adult patients with dyspeptic symptoms to screened Helicobacter pylori infection.

Pancreatic cancer is one of the deadliest and a highly aggressive cancer. Its incidence and mortality are highest in developed countries.  However, in Asia-Pacific region, the incidence and mortality rate of pancreatic cancer are also on increasing trend nowadays. Pancreatic cancer incidence rates increase with older age, the highest in the 7th and 8th decades. Clinical presentation of pancreatic cancer are usually non-specific, largely dependent on tumour size and location, with most patients experience symptoms already late in the disease. Computed tomography is considered the method of choice for diagnosis and staging of pancreatic cancer. Management for pancreatic cancer include surgical resection, radiotherapy, chemotherapy. Only surgical resection considered the potentially curative treatment for pancreatic cancer. Unfortunately, a lot of patients present with disease that is not surgically resectable. Prognosis for pancreatic cancer is very poor, despite surgery in resectable patients. The overall five-year survival rate is about less than 5%